Acipimox

• Description:

  Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].

• Product Name Alternative:

  K-9321

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Carbonic Anhydrase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Acipimox.html

• Purity:

  99.58

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C[N+]([O-])=C(C)C=N1)O

• Molecular Formula:

  C6H6N2O3

• Molecular Weight:

  154.13

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83 (12) :2671-2677.|[2]Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174 (2) :267-72.|[3]Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171 (2) :161-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [51037-30-0]